Article and Video CATEGORIES
Is Nintedanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
Article
Da click aquí para más información y para registrarte ahora
Forum Discussions
Hello Janine,
Thank you for sharing this valuable leukemia playlist—building a reliable knowledge base like this truly makes a difference for everyone navigating such a challenging journey. I appreciate the open...
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on